Vutrisiran
Brand names: Amvuttra · Active ingredient: Vutrisiran Sodium
In short: AMVUTTRA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults. AMVUTTRA is indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascula
What is Vutrisiran used for?
AMVUTTRA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
AMVUTTRA is indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits.
Vutrisiran dosage
The recommended dosage of AMVUTTRA is 25 mg administered by subcutaneous injection once every 3 months .
Missed Dose
If a dose is missed, administer AMVUTTRA as soon as possible. Resume dosing every 3 months from the most recently administered dose.
AMVUTTRA is for subcutaneous use only and should be administered by a healthcare professional.
Syringe Appearance Before and After Use
Before Use | After Use
Preparation and Administration
1.
Prepare the syringe
If stored cold, allow the syringe to warm to room temperature for 30 minutes prior to use.Remove the syringe from the packaging by gripping the syringe body.
Do not touch the plunger rod until ready to inject.
Visually inspect the drug solution for discoloration and particulate matter prior to administration. AMVUTTRA is a sterile, preservative-free, clear, colorless-to-yellow solution. Do not use if it contains particulate matter or if it is cloudy or discolored.Check the following:
Syringe is not damaged, such as cracked or leaking
Needle cap is attached to the syringe
Expiration date on syringe label
Do not use the syringe if any issues are found while checking the syringe.
2.
Choose and prepare the injection site
Choose an injection site from the following areas: the abdomen, thighs, or upper arms.Avoid the following:
5-cm area around the navel
Scar tissue or areas that are reddened, inflamed, or swollen
Clean the chosen injection site.
3.
Prepare the syringe for injection
Hold the syringe body with one hand. Pull the needle cap straight off with other hand and dispose of needle cap immediately. It is normal to see a drop of liquid at the tip of the needle.
Do not touch the needle or let it touch any surface.
Do not recap the syringe.
Do not use the syringe if it is dropped.
4.
Perform the injection
Pinch the cleaned skin.Fully insert the needle into the pinched skin at a 45°-90° angle.
Inject all of the medication.
Push the plunger rod as far as it will go to administer the dose and activate the needle shield.
Release the plunger rod to allow the needle shield to cover the needle.
Do not block plunger rod movement.
5.
Dispose of the syringe
Immediately dispose of the used syringe into a sharps container.
How to take Vutrisiran — instructions & advice from the label
Recommended Vitamin A Supplementation
Inform patients that AMVUTTRA treatment leads to a decrease in serum vitamin A levels. Instruct patients to take the recommended daily allowance of vitamin A. Advise patients to contact their healthcare provider if they experience ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness) and refer them to an ophthalmologist if they develop these symptoms .
Pregnancy
Instruct patients that if they are pregnant or plan to become pregnant while taking AMVUTTRA they should inform their healthcare provider. Inform patients of the potential risk to the fetus, including that AMVUTTRA treatment leads to a decrease in serum vitamin A levels .
Warnings & precautions
Do not take this medicine if: None.
AMVUTTRA treatment leads to a decrease in serum vitamin A levels .
Supplementation at the recommended daily allowance of vitamin A is advised for patients taking AMVUTTRA. Higher doses than the recommended daily allowance of vitamin A should not be given to try to achieve normal serum vitamin A levels during treatment with AMVUTTRA, as serum vitamin A levels do not reflect the total vitamin A in the body.
Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).
Vutrisiran side effects
The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling:
Reduced Serum Vitamin A Levels and Recommended Supplementation
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of AMVUTTRA cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Two Phase 3 randomized, multi-center studies evaluated the safety of AMVUTTRA in 448 transthyretin-mediated amyloidosis (ATTR) patients, including 122 patients with hATTR-PN (HELIOS-A) and 326 patients with ATTR-CM (HELIOS-B) . In both studies, patients were instructed to take the recommended daily allowance of vitamin A .
Polyneuropathy of Hereditary Transthyretin-mediated Amyloidosis
In HELIOS-A, 118 patients received at least 18 months of treatment. The mean duration of treatment was 18.8 months (range: 1.7 to 19.4 months). The median patient age at baseline was 60 years and 65% of the patients were male. Seventy percent of AMVUTTRA-treated patients were Caucasian, 17% were Asian, 3% were Black, and 9% were reported as Other. Forty-four percent of patients had the Val30Met mutation in the transthyretin gene; the remaining patients had one of 21 other mutations. At baseline, 70% of patients were in Stage 1 of the disease and 30% were in Stage 2. …
About this medicine
AMVUTTRA contains vutrisiran, a chemically modified double-stranded small interfering ribonucleic acid (siRNA) that targets mutant and wild-type transthyretin (TTR) messenger RNA (mRNA) and is covalently linked to a ligand containing three N-acetylgalactosamine (GalNAc) residues to enable delivery of the siRNA to hepatocytes.
The structural formula of vutrisiran sodium is presented below.
Dashed lines denote Watson-Crick base pairing
The molecular formula of vutrisiran sodium is C530H672F9N171Na43O323P43S6 with a molecular weight of 17,290 Da. The molecular formula of the free acid is C530H715F9N171O323P43S6 with a molecular weight of 16,345 Da.
AMVUTTRA is supplied as a sterile, preservative-free, clear, colorless-to-yellow solution for subcutaneous injection. Each 0.5 mL of solution contains 25 mg of vutrisiran (equivalent to 26.5 mg vutrisiran sodium), 0.2 mg sodium phosphate monobasic dihydrate, 0.7 mg sodium phosphate dibasic dihydrate, 3.2 mg sodium chloride, water for injection, and sodium hydroxide and/or phosphoric acid to adjust the pH to ~7. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 8db0facb-81b6-4006-9239-27dc6409c5d3. Read the full official label on DailyMed.
Related medicines
Rosuvastatin Semaglutide Hydrochlorothiazide Apixaban Simvastatin Empagliflozin Furosemide Carvedilol